Corvus Pharmaceuticals, Inc. Cash and Restricted Cash
Corvus Pharmaceuticals, Inc. (CRVS) had Cash and Restricted Cash of $18.91 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $18.91M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $40.10M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $4.58M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2.87M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $18.91M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $40.10M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $4.58M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $2.87M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $14.69M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $5.00M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $8.74M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $4.68M 10-Q · filed 2025-11-04 |
| 2024-06-30 | $14.84M 10-Q · filed 2025-08-07 |
| 2024-03-31 | $7.46M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $12.62M 10-K · filed 2026-03-12 |
| 2023-09-30 | $20.11M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $7.66M 10-Q · filed 2024-08-06 |
| 2023-03-31 | $9.65M 10-Q · filed 2024-05-07 |
| 2022-12-31 | $13.16M 10-K · filed 2026-03-12 |
| 2022-09-30 | $24.59M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $28.48M 10-Q · filed 2023-08-08 |
| 2022-03-31 | $31.46M 10-Q · filed 2023-05-08 |
| 2021-12-31 | $63.46M 10-K · filed 2025-03-25 |
| 2021-09-30 | $72.30M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $58.91M 10-Q · filed 2022-08-08 |
| 2021-03-31 | $45.10M 10-Q · filed 2022-05-05 |
| 2020-12-31 | $16.45M 10-K · filed 2024-03-19 |
| 2020-09-30 | $22.98M 10-Q · filed 2021-11-01 |
| 2020-06-30 | $20.70M 10-Q · filed 2021-08-02 |
| 2020-03-31 | $23.50M 10-Q · filed 2021-04-29 |
| 2019-12-31 | $5.15M 10-K · filed 2023-03-28 |
| 2019-09-30 | $9.07M 10-Q · filed 2020-10-29 |
| 2019-06-30 | $30.18M 10-Q · filed 2020-07-30 |
| 2019-03-31 | $38.98M 10-Q · filed 2020-04-30 |
| 2018-12-31 | $39.20M 10-K · filed 2022-03-10 |
| 2018-09-30 | $40.75M 10-Q · filed 2019-10-29 |
| 2018-06-30 | $28.07M 10-Q · filed 2019-08-01 |
| 2018-03-31 | $102.56M 10-Q · filed 2019-05-09 |
| 2017-12-31 | $45.11M 10-K · filed 2021-03-25 |
| 2017-09-30 | $44.10M 10-Q · filed 2018-11-01 |
| 2017-06-30 | $34.09M 10-Q · filed 2018-08-02 |
| 2016-12-31 | $5.05M 10-K · filed 2020-03-09 |
| 2015-12-31 | $4.11M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |